Spravato 28 mg nasal spray clinical trials

A randomized, double-blind, single-center, 2-period cross-over Phase I study to assess the tolerability, safety and pharmacokinetics of antidepressant doses of oral ketamine hydrochloride prolonged release tablets (KET01) compared to intranasal esketamine in healthy male subjects

This study is looking at a new tablet treatment for depression called KET01, comparing it to an existing nasal spray called Spravato. It's an early study to see if KET01 is safe, how the body handles it, and if it causes any unwanted effects in healthy men.